Literature DB >> 15494035

Amylin receptors: molecular composition and pharmacology.

D L Hay1, G Christopoulos, A Christopoulos, P M Sexton.   

Abstract

Several receptors which bind the hormone AMY (amylin) with high affinity have now been identified. The minimum binding unit is composed of the CT (calcitonin) receptor at its core, plus a RAMP (receptor activity modifying protein). The receptors have been named AMY(1(a)), AMY(2(a)) and AMY(3(a)) in accordance with the association of the CT receptor (CT((a))) with RAMP1, RAMP2 and RAMP3 respectively. The challenge is now to determine the localization and pharmacological nature of each of these receptors. Recent attempts to achieve these aims will be briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494035     DOI: 10.1042/BST0320865

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  29 in total

1.  Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols.

Authors:  Ping Cao; Daniel P Raleigh
Journal:  Biochemistry       Date:  2012-03-21       Impact factor: 3.162

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  Cellular assays as portals to seven-transmembrane receptor-based drug discovery.

Authors:  Terry P Kenakin
Journal:  Nat Rev Drug Discov       Date:  2009-07-17       Impact factor: 84.694

4.  Evidence for a partially structured state of the amylin monomer.

Authors:  Sara M Vaiana; Robert B Best; Wai-Ming Yau; William A Eaton; James Hofrichter
Journal:  Biophys J       Date:  2009-12-02       Impact factor: 4.033

5.  Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.

Authors:  Jack H Jhamandas; Zongming Li; David Westaway; Jing Yang; Simran Jassar; David MacTavish
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 6.  Mechanisms of current therapies for diabetes mellitus type 2.

Authors:  Peter M Thulé
Journal:  Adv Physiol Educ       Date:  2012-12       Impact factor: 2.288

7.  The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc).

Authors:  Lynda Whiting; James E McCutcheon; Christina N Boyle; Mitchell F Roitman; Thomas A Lutz
Journal:  Physiol Behav       Date:  2017-03-22

8.  Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.

Authors:  M Feigh; K V Andreassen; A V Neutzsky-Wulff; S T Petersen; C Hansen; A C Bay-Jensen; J E Henriksen; H Beck-Nielsen; C Christiansen; K Henriksen; M A Karsdal
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

9.  A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes.

Authors:  James A Hebda; Ishu Saraogi; Mazin Magzoub; Andrew D Hamilton; Andrew D Miranker
Journal:  Chem Biol       Date:  2009-09-25

10.  Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat.

Authors:  Miranda D Johnson; Sebastien G Bouret; Ambrose A Dunn-Meynell; Christina N Boyle; Thomas A Lutz; Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.